Whilst the outbreak of the latest strain of Coronavirus – Covid-19 – is a scare for healthcare systems and citizens worldwide, it presents an opportunity to pharma and government to reassess the way they work together.
Coronavirus
With Covid-19 surpassing 400,000 cases worldwide, including over 18,000 deaths, the pressure is on the pharma industry to accelerate a vaccine through clinical trials and into patients, as quickly as possible - easier said than done.
That time is of the essence is particularly important to the pharma industry. In recent years, outbreaks of Ebola and SARS caused an influx of activity from pharma players. But when the time came for vaccines to be tested, patient cases had dwindled and companies were unable to recuperate the costs they’d put into research and development (R&D).